Valneva SE (VALN) Non-Current Assets (2020 - 2026)
Valneva SE (VALN) posted Non-Current Assets of $199.7 million for Q1 2026, down 2.69% sequentially from $205.2 million in Q4 2025, and down 2.74% YoY from $205.3 million in Q1 2025.
Valneva SE (VALN) Non-Current Assets (2020 - 2026) Analysis & Trends
Valneva SE has reported Non-Current Assets for 7 years, with the latest figure at $199.7 million in Q1 2026.
- Quarterly Non-Current Assets fell 2.74% year-over-year to $199.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $827.9 million (down 4.47% YoY) and the FY2025 annual result came in at $205.2 million, down 5.68% from the prior year.
- Non-Current Assets fell to $199.7 million in Q1 2026 per VALN's latest filing, from $205.2 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $261.2 million in Q1 2022 and troughed at $199.7 million in Q1 2026.
- A 5-year average of $217.3 million and a median of $213.6 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2024: Non-Current Assets dropped 24.23% in 2022, then grew 7.5% in 2024.
- Over 5 years, Non-Current Assets stood at $200.7 million in 2022, then rose by 5.76% to $212.2 million in 2023, then rose by 1.22% to $214.8 million in 2024, then fell by 4.47% to $205.2 million in 2025, then declined by 2.69% to $199.7 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $199.7 million, $205.2 million, and $210.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Valneva SE | 618.67 Mn | 477.41 Mn | 1.86 Mn | 192.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 192.25 Mn |
| Mar 31, 2026 | 199.70 Mn |
| Dec 31, 2025 | 205.22 Mn |
| Sep 30, 2025 | 210.31 Mn |
| Jun 30, 2025 | 212.70 Mn |
| Mar 31, 2025 | 205.32 Mn |
| Dec 31, 2024 | 214.81 Mn |
| Sep 30, 2024 | 233.92 Mn |
| Jun 30, 2024 | 212.60 Mn |
| Mar 31, 2024 | 213.57 Mn |
| Dec 31, 2023 | 212.22 Mn |
| Sep 30, 2023 | 217.59 Mn |
| Jun 30, 2023 | 218.97 Mn |
| Mar 31, 2023 | 215.39 Mn |
| Dec 31, 2022 | 200.67 Mn |
| Sep 30, 2022 | 223.38 Mn |
| Jun 30, 2022 | 236.17 Mn |
| Mar 31, 2022 | 261.16 Mn |
| Dec 31, 2021 | 264.85 Mn |
| Dec 31, 2020 | 167.80 Mn |